SEC Tracker
Get the app

Recursion Pharmaceuticals RXRX

Recursion Pharmaceuticals raises $200M

Form
8-K
Filed
Importance
Routine
  1. Offered 61,540,000 shares of Class A common stock at $3.25 per share
  2. Gross proceeds expected to be $200M before expenses
  3. Closing expected on October 16, 2026
  4. Cash balance as of September 30, 2026 was $561M

Written from the 8-K on EDGAR. Check the filing before you rely on it.

Open in the appGet the appView on EDGAR

Get an email when Recursion Pharmaceuticals files

Only major filings: results, leadership changes, listing notices and other major events, each with the plain-English summary when we have one or the key facts and the EDGAR link. Routine insider filings never email. Confirm once; unsubscribe in one click.

Similar companies

Companies of similar size in SIC 2836 and related industry codes: the same peer list as the financial tables.

  1. Bausch Health Companies BHC public float $2.0B, Jun 30, 2025
  2. Vericel VCEL public float $2.1B, Jun 30, 2025
  3. Agios Pharmaceuticals AGIO public float $1.9B, Jun 30, 2025
  4. Biocryst Pharmaceuticals BCRX public float $1.9B, Jun 30, 2025
  5. Indivior Pharmaceuticals INDV public float $1.8B, Jun 30, 2025